Edgar Filing: CTI BIOPHARMA CORP - Form 4

CTI BIOPH	ARMA CORP									
Form 4	0017									
February 27	ЛЛ	STATES					E COMMISSIO		PPROVAL	
Washington, D.C. 20549 Check this box if no longer whiat ta								Number: Expires:	3235-0287 January 31, 2005	
subject to					RITIES	FICIAL O	Estimated burden hou response	urs per		
Form 5 obligation may cor <i>See</i> Inst 1(b).	ons Section 170	(a) of the	Public U	Jtility Hol	ding Co		nge Act of 1934, of 1935 or Secti 1940			
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Telling Fred			Symbol	er Name and		C	5. Relationship of Reporting Person(s) to Issuer			
						RP [CTIC]	(Check all applicable)			
(Last) (First) (Middle) 3101 WESTERN AVENUE, SUITE 600				of Earliest T Day/Year) 2017	ransactio	1	X_ Director 10% Owner Officer (give title Other (specify below) below)			
	4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
SEATTLE	, WA 98121						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tat	ole I - Non-I	Derivativ	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution I any (Month/Day/Year)		Date, if	Date, if TransactionAcquired (A) or Code Disposed of (D) y/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)			5. Amount of Securities6. Ownership Form: Direct7. Nature o IndirectBeneficially Owned(D) or IndirectBeneficial BeneficialOwned Following Transaction(s)(Instr. 4)(Instr. 4)				
				Code V	Amount	or (D) Price	(Instr. 3 and 4)			
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities benet	-	-	-			
					infor requ	mation con ired to resp	spond to the colle tained in this forr ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)	

number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

Edgar Filing: CTI BIOPHARMA CORP - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year) (I		(Instr.	8)	or Dispos (D)	(Instr. 3, 4,				(
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 4.25	02/23/2017		A		50,000		<u>(1)</u>	02/22/2027	Common Stock	50,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Telling Fred 3101 WESTERN AVENUE, SUITE 600 SEATTLE, WA 98121	Х						
Signatures							
/s/ Louis A. Bianco, Attorney-in-fact for F Telling	Fred	02/27/2017					
<u>**</u> Signature of Reporting Person		E	Date				

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Plan), subject to the Reporting Persons' continued service through such date or event.

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This stock option was granted on February 23, 2017 and vests on the first to occur of (i) the date that is twelve months after the date of grant, (ii) the first annual meeting of CTIC's shareholders in 2018 at which one or more members of the CTIC Board of Directors are to be elected, or (iii) immediately prior to the occurrence of a Change of Control (as such term is defined in CTIC's 2015 Equity Incentive

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(